Merit Medical Q3 2026 slides: revenue up 8%, guidance raised
Merit Medical Systems (MMSI) reported Q3 2026 revenue of $416.2M, up 8.4% YoY, with non-GAAP EPS of $1.12, up 21.7%. GAAP net income rose 52.4% to $42.3M. Operating margin expanded to 14.1%. The company raised full-year non-GAAP EPS guidance to $4.33-$4.37. Shares closed up 1.28%.
How this was made
The 30-second read
Why it matters
The key tradable update is the raised full-year non-GAAP EPS range alongside largely steady revenue guidance, with margin drivers (platinum costs, freight, manufacturing variances) and a stated mitigation plan (alternative to platinum ramp).
Market read
Guidance raise plus detailed margin and cash-flow drivers provide a clear near-term catalyst for MMSI positioning into subsequent quarters.
What to watch
Working capital investments reduced operating cash flow and free cash flow year over year, which could matter for near-term capital allocation and quality-of-earnings perceptions.
Background
Merit Medical Systems presented its Q3 2026 results and accompanying slide deck, reporting revenue growth, margin changes, and updated full-year guidance.
Ticker impact
Merit Medical reported Q3 revenue up 8.4% and raised full-year 2026 non-GAAP EPS guidance to $4.33-$4.37.
Likely upward bias as the market reprices the raised EPS outlook, tempered by concerns about sustaining margins amid raw-material and logistics headwinds.
The article includes both the beat and the explicit guidance raise, while also detailing margin pressure drivers and a platinum alternative ramp plan.
Market effects
Signals improving profitability execution in medical devices, while highlighting ongoing input-cost and logistics pressures that may affect peers’ margin expectations.
Domestic outperformance (U.S. revenue up 11%) versus weaker China pricing/regulatory pressure may influence regional demand expectations for procedure-driven device makers.
Guidance and margin commentary can affect broader sentiment toward medtech earnings durability amid cost inflation and FX headwinds.
Counterpoint
Raised EPS guidance may still be vulnerable if platinum substitution and freight normalization do not materialize as expected, given gross margin compression in the quarter.
Key entities
- companyMerit Medical Systems
NASDAQ-listed medical device maker that reported Q3 2026 results and raised full-year 2026 non-GAAP EPS guidance.
- acquired_companySolo Pace, Inc.
Temporary pacing technology acquisition completed in October 2026, cited as part of Merit Medical’s portfolio expansion.
- acquired_companyView Point Medical, Inc.
Acquisition completed in April 2026, noted as progressing with slower-than-planned integration elements.
